Duration
4 Years
Targeting hope
DNA methylation markers to predict
About METHYLOMIC
METHYLOMIC is committed to bringing personalised treatment-selection in Crohn’s disease and other immune-mediated inflammatory diseases to clinical practice.
Budget
10 Million
18 partners
9 countries
Why METHYLOMIC?
Crohn's disease
The prime purpose of METHYLOMIC is to develop and clinically validate a novel epigenetic biomarker tool that enables the identification of most optimal treatments for individual patients and hence to ensure an effective and efficient use of existing and broadly prescribed biologicals for Crohn´s disease (CD).
Rheumatoid Arthritis
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur commodo tristique arcu, eget eleifend velit egestas venenatis. In sed sollicitudin elit, et varius nibh. In id elit magna. Curabitur felis tortor, vestibulum eget maximus quis, sagittis sit amet felis. Nam vehicula mauris purus, at dignissim quam consectetur ac. Vestibulum sed elementum tortor, vel sagittis ligula.
Psoriasis
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur commodo tristique arcu, eget eleifend velit egestas venenatis. In sed sollicitudin elit, et varius nibh. In id elit magna. Curabitur felis tortor, vestibulum eget maximus quis, sagittis sit amet felis. Nam vehicula mauris purus, at dignissim quam consectetur ac. Vestibulum sed elementum tortor, vel sagittis ligula.